Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Coiffier, Bertrand; Leprêtre, Stéphane; Møller Pedersen, Lars; Gadeberg, Ole; Fredriksen, Henrik; H. J. van Oers, Marinus; E. Wooldridge, James; Kłoczko, Janusz; Hołowiecki, Jerzy; Hellmann, Andrzej; Walewski, Jan; Folden Flensburg, Mimi; Holm Petersen, Jørgen; Robak, Tadeusz

doi:10.1182/blood-2007-09-111781

Public

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Published in Blood • Nov 14, 2007

Authors:

Bertrand Coiffier

Stéphane Leprêtre

Lars Møller Pedersen

Abstract

Safety and efficacy of the fully human anti-CD20 monoclonal antibody, ofatumumab, was analyzed in a multicenter dose-escalating study including 33 patients with relapsed or refractory chronic lymphocytic leukemia. Three cohorts of 3 (A), 3 (B), and 27 (C) patients received 4, once weekly, infusions ...

Subject

Ofatumumab

Medicine

Chronic lymphocytic leukemia

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!